首页 > 最新文献

Astim Allerji Immunoloji最新文献

英文 中文
Diagnostic Management of Chronic Granulomatous Disease 慢性肉芽肿性疾病的诊断处理
IF 0.2 Q4 ALLERGY Pub Date : 2023-04-07 DOI: 10.21911/aai.237
M. Y. Koker
{"title":"Diagnostic Management of Chronic Granulomatous Disease","authors":"M. Y. Koker","doi":"10.21911/aai.237","DOIUrl":"https://doi.org/10.21911/aai.237","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48023277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Frequency and Severity of COVID-19 in Patients Receiving Biological Agents and Risk Factors: Experience of an Allergy Clinic 新冠肺炎在接受生物制剂和危险因素治疗的患者中的频率和严重程度:过敏诊所的经验
IF 0.2 Q4 ALLERGY Pub Date : 2023-04-07 DOI: 10.21911/aai.141
Sadan Soyyigit, Ş. Beyaz, Zeynep Celebi Sozener
Objective: The effect of biological agents used in severe allergic diseases on the risk of coronavirus disease 2019 (COVID-19) and the course of the disease still remains unclear. The aim of the study was to evaluate retrospectively the frequency and severity of COVID-19 to determine risk factors and to present real-life data in patients using biological agents.Materials and Methods: Patients who have used omalizumab or mepolizumab for at least six months were questioned retrospectively in terms of a history of COVID-19. Patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) or serological IgG positivity, symptoms, lung involvement, the need for supplemental oxygen, hospital and intensive care admission, and mortality were queried. Results: Of the 71 patients (omalizumab/mepolizumab: 51/20) included in the study, the average age was 37.2 +/- 12.9, and the female/ male ratio was 46/25. Of the 11 patients (omalizumab/mepolizumab: 6/5) with SARS-CoV-2 positivity, two were hospitalized for pneumonia and needed oxygen. However, intensive care was not required and they survived. There was no significant difference between mepolizumab users who had COVID-19 and those who did not in terms of baseline and post-treatment 6th-month eosinophil values (p= 0.7, p= 0.59, respectively). It was established that eosinopenia developing after treatment did not increase the risk of COVID-19 in patients using mepolizumab [RR (95% Cl) 0.99 (0.97-1.02), p=0.88].Conclusion: According to our single center data, we found the risk of severe COVID-19 in patients using biological agents to be quite low. Especially, eosinopenia that developed after mepolizumab treatment did not constitute a risk factor for the severity of COVID-19.
目的:用于严重过敏性疾病的生物制剂对2019冠状病毒病(新冠肺炎)风险和病程的影响仍不清楚。该研究的目的是回顾性评估新冠肺炎的频率和严重程度,以确定风险因素,并提供使用生物制剂的患者的真实数据。材料和方法:根据新冠肺炎病史,对使用奥马珠单抗或美泊珠单抗至少六个月的患者进行回顾性调查。对严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)聚合酶链式反应(PCR)或血清学IgG阳性患者、症状、肺部受累、是否需要补充氧气、住院和重症监护以及死亡率进行了询问。结果:在纳入研究的71名患者中(奥马珠单抗/美宝珠单抗:51/20),平均年龄为37.2+/-12.9,女性/男性比例为46/25。在11名严重急性呼吸系统综合征冠状病毒2型阳性患者中(奥马珠单抗/美宝珠单抗:6/5),有两名因肺炎住院,需要吸氧。然而,不需要重症监护,他们活了下来。在基线和治疗后6个月的嗜酸性粒细胞值方面,患有新冠肺炎的美波利珠单抗使用者与未患有的美波利珠单抗使用者之间没有显著差异(分别为p=0.7和p=0.59)。研究表明,在使用美泊珠单抗的患者中,治疗后出现嗜酸性粒细胞减少症不会增加患新冠肺炎的风险[RR(95%Cl)0.99(0.97-1.02),p=0.88]。结论:根据我们的单中心数据,我们发现使用生物制剂的患者患严重新冠肺炎的风险非常低。特别是,美宝珠单抗治疗后出现的伊红细胞减少症并不构成新冠肺炎严重程度的危险因素。
{"title":"The Frequency and Severity of COVID-19 in Patients Receiving Biological Agents and Risk Factors: Experience of an Allergy Clinic","authors":"Sadan Soyyigit, Ş. Beyaz, Zeynep Celebi Sozener","doi":"10.21911/aai.141","DOIUrl":"https://doi.org/10.21911/aai.141","url":null,"abstract":"Objective: The effect of biological agents used in severe allergic diseases on the risk of coronavirus disease 2019 (COVID-19) and the course of the disease still remains unclear. The aim of the study was to evaluate retrospectively the frequency and severity of COVID-19 to determine risk factors and to present real-life data in patients using biological agents.Materials and Methods: Patients who have used omalizumab or mepolizumab for at least six months were questioned retrospectively in terms of a history of COVID-19. Patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) or serological IgG positivity, symptoms, lung involvement, the need for supplemental oxygen, hospital and intensive care admission, and mortality were queried. Results: Of the 71 patients (omalizumab/mepolizumab: 51/20) included in the study, the average age was 37.2 +/- 12.9, and the female/ male ratio was 46/25. Of the 11 patients (omalizumab/mepolizumab: 6/5) with SARS-CoV-2 positivity, two were hospitalized for pneumonia and needed oxygen. However, intensive care was not required and they survived. There was no significant difference between mepolizumab users who had COVID-19 and those who did not in terms of baseline and post-treatment 6th-month eosinophil values (p= 0.7, p= 0.59, respectively). It was established that eosinopenia developing after treatment did not increase the risk of COVID-19 in patients using mepolizumab [RR (95% Cl) 0.99 (0.97-1.02), p=0.88].Conclusion: According to our single center data, we found the risk of severe COVID-19 in patients using biological agents to be quite low. Especially, eosinopenia that developed after mepolizumab treatment did not constitute a risk factor for the severity of COVID-19.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48153001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Clinical and Laboratory Features of Patients with Ataxia-Telangiectasia 共济失调毛细血管扩张症患者的临床和实验室特征评价
IF 0.2 Q4 ALLERGY Pub Date : 2023-04-07 DOI: 10.21911/aai.006
M. Kiliç, Omer Gunbey, E. Taşkin, Bunyamin Dag, Elif Kucuk, Fatma Gunbey, Aşkın Şen
{"title":"Evaluation of Clinical and Laboratory Features of Patients with Ataxia-Telangiectasia","authors":"M. Kiliç, Omer Gunbey, E. Taşkin, Bunyamin Dag, Elif Kucuk, Fatma Gunbey, Aşkın Şen","doi":"10.21911/aai.006","DOIUrl":"https://doi.org/10.21911/aai.006","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46912671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-Vitro Evaluation of Immunomodulation Effects of Mesenchymal Stem Cell-Derived Exosomes in Refractory Chronic Spontaneous Urticaria 间充质干细胞来源的外泌体对难治性慢性自发性荨麻疹免疫调节作用的体外评价
IF 0.2 Q4 ALLERGY Pub Date : 2023-04-07 DOI: 10.21911/aai.120
Alper Tunga Ozdemir, C. Kırmaz, Rabia Bilge OZGUL OZDEMIR, M. Oztatlici, Pinar KILICARSLAN SONMEZ, M. Tuğlu
{"title":"In-Vitro Evaluation of Immunomodulation Effects of Mesenchymal Stem Cell-Derived Exosomes in Refractory Chronic Spontaneous Urticaria","authors":"Alper Tunga Ozdemir, C. Kırmaz, Rabia Bilge OZGUL OZDEMIR, M. Oztatlici, Pinar KILICARSLAN SONMEZ, M. Tuğlu","doi":"10.21911/aai.120","DOIUrl":"https://doi.org/10.21911/aai.120","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48980100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Profiles of Biological Therapies Used in Asthma Treatment 用于哮喘治疗的生物疗法的安全性概况
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.091
G. PAÇACI ÇETİN, B. Arslan, I. Yilmaz
{"title":"Safety Profiles of Biological Therapies Used in Asthma Treatment","authors":"G. PAÇACI ÇETİN, B. Arslan, I. Yilmaz","doi":"10.21911/aai.091","DOIUrl":"https://doi.org/10.21911/aai.091","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45867393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Distribution of Sensitization to Common Inhalant Allergens in Adult Allergic Rhinitis Patients with or without Asthma in Batman 成人变应性鼻炎伴或不伴哮喘患者对常见吸入性变应原的致敏性分布
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.076
C. Tuzer
{"title":"The Distribution of Sensitization to Common Inhalant Allergens in Adult Allergic Rhinitis Patients with or without Asthma in Batman","authors":"C. Tuzer","doi":"10.21911/aai.076","DOIUrl":"https://doi.org/10.21911/aai.076","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42592003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Internet Addiction on Asthma Control and Medication Adherence 网络成瘾对哮喘控制和药物依从性的影响
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.685
A. F. Kalpaklioglu, A. Baccioglu, B. Dumanoğlu, M. Poyraz, Sümeyra ALAN YALIM, Gulistan Alpagat
{"title":"The Effect of Internet Addiction on Asthma Control and Medication Adherence","authors":"A. F. Kalpaklioglu, A. Baccioglu, B. Dumanoğlu, M. Poyraz, Sümeyra ALAN YALIM, Gulistan Alpagat","doi":"10.21911/aai.685","DOIUrl":"https://doi.org/10.21911/aai.685","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45394405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pneumococcal Vaccination is a Challenge of Pediatric Allergists 肺炎球菌疫苗接种是儿科变态反应学家面临的挑战
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.011
Sinem Polat Terece, H. I. Ertoy Karagol, A. Bakirtas
Objective: An increased risk of invasive pneumococcal disease (IPD) has been reported in children with asthma before the introduction of pneumococcal vaccines (PVs). However, the evidence is limited after PV entered the routine immunization schedule. We aimed to investigate whether pediatric allergists recommend additional PV (aPV) to asthmatic children and if so whether there are any asthma-specific risk factors they consider. We also wanted to determine any changes in their recommendations during the COVID-19 pandemic. Materials and Methods: A questionnaire was e-mailed to all members of the Academy of Pediatric Allergy and Asthma in Turkey. The questionnaire was filled online and consisted of 14 questions. Results: The questionnaire was e-mailed to 220 members. The response rate was 56.3% and 60.5% of PA recommended aPV. The most frequent asthma specific factors for aPV were severe asthma (70.2%), long term oral corticosteroid use (65.3%) and frequent exacerbations / hospitalizations (62.9%). COVID-19 pandemic increased the rate of questions asked to PA about aPV for asthmatic children compared to previous periods (75.8 vs 33.9%) (p<0.001) and %27 of PA changed their recommendations in favor of aPV during pandemic.Conclusion: Asthmatic children is not infrequent. Severe asthma and related factors seem to be the leading reasons to recommend aPV for asthmatic children. The aPV recommendation by PA is increased during COVID-19 pandemic.
目的:据报道,在引入肺炎球菌疫苗(PV)之前,哮喘儿童患侵袭性肺炎球菌疾病(IPD)的风险增加。然而,PV进入常规免疫计划后,证据有限。我们的目的是调查儿科过敏专科医生是否建议哮喘儿童服用额外的PV(aPV),如果是,他们是否考虑了任何哮喘特异性风险因素。我们还想确定在新冠肺炎大流行期间他们的建议是否有任何变化。材料和方法:通过电子邮件向土耳其儿科过敏和哮喘学会的所有成员发送了一份问卷。问卷是在线填写的,共有14个问题。结果:问卷已通过电子邮件发送给220名成员。有效率分别为56.3%和60.5%。aPV最常见的哮喘特异性因素是严重哮喘(70.2%),长期口服皮质类固醇使用(65.3%)和频繁恶化/住院(62.9%)。与前一时期相比,新冠肺炎大流行增加了向PA询问哮喘儿童aPV问题的比率(75.8%对33.9%)(p<0.001),并且在大流行期间,PA的%27改变了他们的建议,支持aPV。结论:哮喘儿童并不罕见。严重哮喘和相关因素似乎是推荐哮喘儿童使用aPV的主要原因。在新冠肺炎大流行期间,PA的aPV建议增加。
{"title":"Pneumococcal Vaccination is a Challenge of Pediatric Allergists","authors":"Sinem Polat Terece, H. I. Ertoy Karagol, A. Bakirtas","doi":"10.21911/aai.011","DOIUrl":"https://doi.org/10.21911/aai.011","url":null,"abstract":"Objective: An increased risk of invasive pneumococcal disease (IPD) has been reported in children with asthma before the introduction of pneumococcal vaccines (PVs). However, the evidence is limited after PV entered the routine immunization schedule. We aimed to investigate whether pediatric allergists recommend additional PV (aPV) to asthmatic children and if so whether there are any asthma-specific risk factors they consider. We also wanted to determine any changes in their recommendations during the COVID-19 pandemic. Materials and Methods: A questionnaire was e-mailed to all members of the Academy of Pediatric Allergy and Asthma in Turkey. The questionnaire was filled online and consisted of 14 questions. Results: The questionnaire was e-mailed to 220 members. The response rate was 56.3% and 60.5% of PA recommended aPV. The most frequent asthma specific factors for aPV were severe asthma (70.2%), long term oral corticosteroid use (65.3%) and frequent exacerbations / hospitalizations (62.9%). COVID-19 pandemic increased the rate of questions asked to PA about aPV for asthmatic children compared to previous periods (75.8 vs 33.9%) (p<0.001) and %27 of PA changed their recommendations in favor of aPV during pandemic.Conclusion: Asthmatic children is not infrequent. Severe asthma and related factors seem to be the leading reasons to recommend aPV for asthmatic children. The aPV recommendation by PA is increased during COVID-19 pandemic.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41430175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship of Fatty Acid Binding Protein 4 with Asthma and Severity of Asthma 脂肪酸结合蛋白4与哮喘及哮喘严重程度的关系
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.021
S. Demir, Derya Unal, D. Sonmez, O. Ozdemir, B. Berçik İnal
{"title":"Relationship of Fatty Acid Binding Protein 4 with Asthma and Severity of Asthma","authors":"S. Demir, Derya Unal, D. Sonmez, O. Ozdemir, B. Berçik İnal","doi":"10.21911/aai.021","DOIUrl":"https://doi.org/10.21911/aai.021","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42458448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Patient Presenting with Chronic Mucocutaneous Candidiasis: A Novel IL12RB1 Mutation 一例慢性粘膜皮肤念珠菌感染患者:一个新的IL12RB1突变
IF 0.2 Q4 ALLERGY Pub Date : 2022-12-07 DOI: 10.21911/aai.014
S. Esenboğa, Hacer Neslihan Bildik, M. Ocak, D. Çağdaş, I. Tezcan
{"title":"A Patient Presenting with Chronic Mucocutaneous Candidiasis: A Novel IL12RB1 Mutation","authors":"S. Esenboğa, Hacer Neslihan Bildik, M. Ocak, D. Çağdaş, I. Tezcan","doi":"10.21911/aai.014","DOIUrl":"https://doi.org/10.21911/aai.014","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47997769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Astim Allerji Immunoloji
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1